Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...

Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...

Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other ...

Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...

Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.

Prices displayed are informational. Learn more Recursion Pharmaceuticals (RXRX) said Thursday it priced an offering of 61.5 million shares at $3.25 each to raise gross proceeds of about $200 million.

Most patients (21 of 26; 80.8%) had TRAEs of Grade 2 or lower, consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Grade 3 ...

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...

Recursion Pharmaceuticals (NASDAQ: RXRX) priced an underwritten public offering of 61,540,000 shares of its Class A common stock at $3.25 per share, according to a press release issued Oct. 15, ...

Since I called it three times in the recursion, the return process also happens three times. Even though I understood it in ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology™ company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium™ company. Vium’s ...